Meda License, Development and Supply Agreements (Tables)

6 Months Ended

Jun. 30, 2012

Meda License, Development and Supply Agreements [Abstract]

Summary of contractual rights, obligations and related cash flows

	Cash flows received and revenue deferred
Contractual Rights and Obligations	June 30, 2012			December 31, 2011
North America
License rights to ONSOLIS ® (BEMA® Fentanyl) and milestone payments	$	59,800,000		$	59,800,000
Research and Development Services for:
•       Non-cancer subsequent indication of product and further development of initial product	$	1,541,570		$	1,541,570
Total North America Agreement Milestones	$	61,341,570		$	61,341,570
Europe and Rest of World
License rights to BREAKYL™ (BEMA ® Fentanyl) and milestone payments	$	10,500,000		$	8,000,000
Research and Development Services for:
•       BREAKYL™ product through governmental approval in an E.U. country	$	4,548,720		$	4,548,720
Total Europe and Rest of World Milestones	$	15,048,720		$	12,548,720
Total All Milestones	$	76,390,290		$	73,890,290
Release of Milestones upon and subsequent to first sale	$	(59,834,770	)	$	(59,735,570	)
Remaining Deferred Revenue	$	16,555,520		$	14,154,720